Diagnóstico y tratamiento de la tuberculosis con resistencia a fármacos

World Health Organization. Global tuberculosis report 2016. World Health Organization Document. 2016;WHO/HTM/TB/2016.13:1-194. Caminero, 2013, Tuberculosis: Are we making it incurable? (Editorial), Eur Respir J, 42, 5, 10.1183/09031936.00206712 World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization Document. 2006;WHO/HTM/TB/2006.361:1-174. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. Emergency update 2008. World Health Organization Document. 2008;WHO/HTM/TB/2008.402:1-247. World Health Organization. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization Document. 2014;WHO/HTM/TB/2014.11:1-403. Caminero, 2013, 2013 Mukherjee, 2003, 2003 World Health Organization. Treatment Guidelines for drug-resistant tuberculosis. 2016 Update. WHO/HTM/TB/201604. 2016. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. 2011 update. World Health Organization Document. 2011; WHO/HTM/TB/2011.6:1-33. Organization, 2014 García-García, 2011, Social, clinical and microbiological differential characteristics of tuberculosis among immigrants in Spain, PLoS ONE, 6, e16272, 10.1371/journal.pone.0016272 Blanquer, 2015, Resistencia a fármacos antituberculosos de primera línea en España durante 2010-2011. Estudio RETUBES, Arch Bronconeumol, 51, 24, 10.1016/j.arbres.2014.06.001 González-Martín, 2010, Documento de consenso sobre diagnóstico, tratamiento y prevención de la tuberculosis. Documento conjunto de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y de la Sociedad Española de Neumología y Cirugía Torácica (SEPAR), Arch Bronconeumol, 46, 255, 10.1016/j.arbres.2010.02.010 Weyer, 2013, Rapid molecular TB diagnosis: Evidence, policy making and global implementation of Xpert MTB/RIF, Eur Respir J, 42, 252, 10.1183/09031936.00157212 Ruiz-Manzano, 2008, Diagnóstico y tratamiento de la tuberculosis, Arch Bronconeumol, 44, 551, 10.1157/13126836 Caminero, 2010, Multidrug-resistant tuberculosis: epidemiology, risk factors and case finding [State of the Art series. Drug-resistant tuberculosis. Number 4 in the series], Int J Tuberc Lung Dis, 14, 382 World Health Organization. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children. Policy update. World Health Organization Document. 2013; WHO/HTM/TB/2013.14:1-89. Caminero, 2005, Management of multidrug-resistant tuberculosis and patients in retreatment, Eur Respir J, 25, 928, 10.1183/09031936.05.00103004 Kipiani, 2014, Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis, Clin Infect Dis, 59, 1559, 10.1093/cid/ciu631 Jacobson, 2013, Implementation of GenoType MTBDRplus reduces time to multidrug-resistant tuberculosis therapy initiation in South Africa, Clin Infect Dis, 56, 503, 10.1093/cid/cis920 Seifert, 2015, Genetic mutations associated with isoniazid resistance in Mycobacterium tuberculosis: A systematic review, PLoS ONE, 10, e0119628, 10.1371/journal.pone.0119628 Ando, 2010, Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis, Antimicrob Agents Chemother, 54, 1793, 10.1128/AAC.01691-09 Cambau, 2015, Revisiting susceptibility testing in MDR-TB by a standardized quantitative phenotypic assessment in a European multicentre study, J Antimicrob Chemother, 70, 686, 10.1093/jac/dku438 Katiyar, 2008, A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis, Int J Tuberc Lung Dis, 12, 129 Van Deun, 2010, Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis, Am J Respir Crit Care Med, 182, 684, 10.1164/rccm.201001-0077OC Aung, 2014, Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients, Int J Tuberc Lung Dis, 18, 1180, 10.5588/ijtld.14.0100 Piubello, 2014, High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: No relapses, Int J Tuberc Lung Dis, 18, 1188, 10.5588/ijtld.13.0075 Nunn, 2014, Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): Study protocol for a randomized controlled trial, Trials, 15, 353, 10.1186/1745-6215-15-353 Feng, 2013, Rapid diagnosis of drug resistance to fluoroquinolones, amikacin, capreomycin, kanamycin and ethambutol using genotype MTBDRsl assay: A meta-analysis, PLoS ONE, 8, e55292, 10.1371/journal.pone.0055292 Theron, 2014, The diagnostic accuracy of the GenoType® MTBDRsl assay for the detection of resistance to second-line anti-tuberculosis drugs, Cochrane Database Syst Rev, 10, 10.1002/14651858.CD010705.pub2 Lacoma, 2012, GenoTypeMTBDRsl for molecular detection of second-line-drug and ethambutol resistance in Mycobacterium tuberculosis strains and clinical samples, J Clin Microbiol, 50, 30, 10.1128/JCM.05274-11 Brossier, 2016, Performance of the new version (2.0) of the GenoTypeMTBDRsl test for detection of resistance to second-line drugs in multidrug-resistant Mycobacterium tuberculosis complex strains, J Clin Microbiol, 54, 1573, 10.1128/JCM.00051-16 World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance. World Health Organization Document. 2016;WHO/HTM/TB/2016.07 1-43. Iseman, 1993, Treatment of multidrug-resistant tuberculosis, N Engl J Med, 329, 784, 10.1056/NEJM199309093291108 Fox, 1999, Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications, Int J Tuberc Lung Dis, 3, S231 Caminero, 2012, Chapter 12. Treatment of TB, Eur Respir Monogr, 58, 154 Caminero, 2010, Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis, Lancet Infect Dis, 10, 621, 10.1016/S1473-3099(10)70139-0 Caminero, 2015, Classification of anti-TB drugs: A new potential proposal based on the most recent evidence, Eur Respir J, 46, 887, 10.1183/13993003.00432-2015 Falzon, 2013, Resistance to fluoroquinolones and second-line injectable drugs: Impact on multidrug-resistant TB outcomes, Eur Respir J, 42, 156, 10.1183/09031936.00134712 Johnston, 2009, Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis, PLoS ONE, 4, e6914, 10.1371/journal.pone.0006914 Lee, 2012, Linezolid for treatment of chronic extensively drug-resistant tuberculosis, N Engl J Med, 367, 1508, 10.1056/NEJMoa1201964 Tang, 2015, Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: A study in China, Eur Respir J, 45, 161, 10.1183/09031936.00035114 Sorgiu, 2012, Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis, Eur Respir J, 40, 1430, 10.1183/09031936.00022912 Rustomjee, 2008, Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis, Antimicrob Agents Chemother., 52, 2831, 10.1128/AAC.01204-07 Diacon, 2009, The diarylquinoline TMC207 for multidrug-resistant tuberculosis, N Engl J Med, 360, 2397, 10.1056/NEJMoa0808427 Diacon, 2014, Multidrug-resistant tuberculosis and culture conversion with bedaquiline, N Engl J Med, 371, 723, 10.1056/NEJMoa1313865 Diacon, 2011, Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients, Int J Tuberc Lung Dis, 15, 949, 10.5588/ijtld.10.0616 Gler, 2012, Delamanid for multidrug-resistant pulmonary tuberculosis, N Engl J Med, 366, 2151, 10.1056/NEJMoa1112433 Skipconoka, 2013, Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis, Eur Respir J, 41, 1393, 10.1183/09031936.00125812 Diacon, 2012, 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial, Lancet, 380, 986, 10.1016/S0140-6736(12)61080-0 Diacon, 2015, Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline, Am J Respir Crit Care Med, 191, 943, 10.1164/rccm.201410-1801OC Global Drug-resistant TB Initiative (GDI). A Working group of the stop TB partnership. The evaluation of effectiveness and safety of a shorter standardized treatment regimen for multidrug-resistant tuberculosis. Geneva: Stop TB Partneship; 2015. Hwang, 2013, Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: A meta-analysis, Int J Tuberc Lung Dis, 17, 1257, 10.5588/ijtld.12.0863 De Lorenzo, 2013, Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB, Eur Respir J, 41, 1386, 10.1183/09031936.00124312 Caminero, 2010, Tratamiento de la tuberculosis según el diferente patrón de resistencias, Med Clin (Barc), 134, 173, 10.1016/j.medcli.2008.12.024 2009, Plan para la prevención y control de la tuberculosis en España, Arch Bronconeumol, 45, 139, 10.1016/j.arbres.2009.01.001 Orenstein, 2009, Treatment outcome among patients with multidrug-resistant tuberculosis: Systematic review and meta-analysis, Lancet Infect Dis, 9, 153, 10.1016/S1473-3099(09)70041-6 Ahuja, 2012, Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: An individual patient data meta-analysis of 9,153 patients, PLoS Med, 9, e1001300, 10.1371/journal.pmed.1001300 Marrone, 2013, Surgical interventions for drug-resistant tuberculosis: A systematic review and meta-analysis, Int J Tuberc Lung Dis, 17, 6, 10.5588/ijtld.12.0198 World Health Organization. Definitions and reporting framework for tuberculosis-2013 revision. World Health Organization Document. 2013;WHO/HTM/TB/2013.2:1-40. Lange, 2014, Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis: A TBNET consensus statement, Eur Respir J, 44, 23, 10.1183/09031936.00188313